Tuesday, Aug 8, 2000
South San Francisco, Calif. -- August 8, 2000 --Genentech, Inc. (NYSE: DNA) announced the appointment of Joseph S. McCracken DVM, MS, to vice president, Business Development. McCracken reports to Myrtle Potter, executive vice president of Commercial Operations and chief operating officer.
"Joe brings a wealth of experience in business development to Genentech," said Potter. "With more than fifteen years of experience in science and business development in biotechnology and pharmaceutical companies, I am sure he will be an asset to Genentech and a success in this pivotal position."
McCracken, 47, is returning to Genentech after a seven year absence. He most recently served as vice president of Technology Licensing and Alliances at Aventis Pharmaceuticals in Bridgewater, NJ. Prior to that position, his role was vice president, Worldwide Business and Technology Development at Rhone-Poulenc Rorer. During his earlier term at Genentech, McCracken served in many capacities, culminating in the position of Representative Director, Genentech Limited Tokyo.
He holds a Bachelor of Science degree in Microbiology, a Master of Science in Pharmacology and a Doctorate of Veterinary Medicine from Ohio State University.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved biotechnology products stem from Genentech science. Genentech markets nine biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #